An experimental, biologic treatment, Brodulamab, achieved 100 percent reduction in Psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers. The study drug, Brodulamab, is a monoclonal antibody, akin to proteins built by the human immune system to recognize and block specific target molecules. A therapeutic antibody, Brodulamab was designed to block the function of the immune signaling protein interleukin 17 (IL-17).
If not blocked, IL-17 docks into specifically shaped proteins, IL-17 receptors, to pass on signals that contribute to abnormal, psoriatic inflammation. "Brodulamab is the only IL-17 receptor antagonist in clinical development," said Mark Lebwohl, MD, Sol and Clara Kest Professor and Chairman of the Kimberly and Eric J. Waldman Department of Dermatology,…
